News

New indication approved for Guerbet’s Lipiodol® Ultra Fluid

Guerbet announced today that it has been granted approval for a new indication for Lipiodol® Ultra Fluid in Belgium, Ireland, Portugal, Hong-Kong and the Philippines, for selective hepatic intra-arterial injection for visualization, localization and vectorization during conventional trans-arterial chemoembolization (cTACE) of tumors in adults with known, intermediate-stage hepatocellular carcinoma (HCC).

 

We use cookies to improve your website experience and to gain insights into our websites’ users and traffic to make it even better. By continuing your navigation on our site without modifying the setting of your cookies, you accept the use of cookies. OKFind out more